PHARMACOEPIDEMIOLOGICAL ANALYSIS OF THE USE OF ANTIPLATELET AGENTS IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING
Foreign scientific studies have shown that the usual standard dose of drugs patients give different pharmacological response: some concentration of drugs in the blood is overestimated, which leads to the development of adverse reactions; others - understated, and treatment becomes ineffective; third - there is a paradoxical reaction that can lead to death. To this end, the rational use of antiplatelets in patients undergoing coronary artery bypass grafting was studied and the incidence of restenosis in patients after stenting was revealed. 197 case histories of patients with CABG were analyzed.